Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

SHARE